De-escalation radiation strategy for advanced head and neck cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory study focuses on patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) who receive two cycles of pembrolizumab immunotherapy combined with albumin-bound paclitaxel and cisplatin chemotherapy. Following this induction therapy, participants undergo definitive concurrent radiochemotherapy. A follow-up examination occurs three months post-radiotherapy to assess the need for salvage surgery or additional systemic therapy based on the results. The study aims to evaluate the effectiveness of this de-escalation approach in managing LAHNSCC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥18 years old, with medical decision-making capacity
2. Signed informed consent
3. ECOG score of 0-1
4. Pathologically diagnosed with oral cancer, oropharyngeal cancer, laryngeal cancer, or hypopharyngeal cancer
5. Exclusion of distant metastasis
6. Clearly evaluable lesion (per RECIST 1.1 criteria)
7. Expected life span ≥6 months
8. Laboratory test results meet the following requirements: WBC ≥ 3×10\^9/L, ANC ≥ 2.0×10\^9/L, PLT ≥ 80×10\^9/L, Hb ≥ 80g/L (according to the normal standards of the central laboratory); Liver function: Total bilirubin, ALT, and AST all ≤ 1.5x UNL (upper normal limit); AST (SGOT)/ALT (SGPT) ≤ 2.5 x IULN (upper normal limit); Kidney function: Cr ≤ 1.5x UNL (upper normal limit), and creatinine clearance rate ≥ 60 ml/min (calculated using the Cockcroft and Gault formula); Thyroid function T3 and T4 within the normal range (hypothyroidism can be corrected with oral thyroid hormone supplementation); Heart function: All three cardiac enzymes and pro-BNP within the normal range, no history of heart attack; Adrenal function: Normal cortisol secretion function or correctable based on endocrine assessment
9. HBV-infected patients with HBV-DNA copy numbers less than 500 IU/ml
10. No history of other malignant tumors in the past 5 years (excluding basal cell carcinoma of the skin and thyroid cancer).

Exclusion Criteria:

1. No indications for curative radiotherapy or contraindications to radiochemotherapy.
2. Clinical factors identified by the investigator that could potentially affect the completion of the study protocol (such as bleeding, active infection, or mental factors).
3. Patients requiring long-term maintenance steroid therapy (including oral and intravenous use); local use or inhalation can be included in the study.
4. Previous history of autoimmune diseases or in the active phase of the disease \[including but not limited to inflammatory bowel disease (IBD), rheumatoid arthritis, autoimmune hepatitis, systemic sclerosis (scleroderma and its variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barré syndrome)\], vitiligo, and correctable endocrine deficiencies such as hypothyroidism and physiological cortisol deficiency can be included in the study and are not exclusion criteria.
5. History of active tuberculosis or non-infectious pneumonia or any clinical evidence.
6. Active phase of viral hepatitis, HBV DNA \> 500 IU/ml.
7. Acquired Immunodeficiency Syndrome (AIDS).
8. Concurrent severe medical conditions (including heart diseases) with coexisting diseases or conditions affecting the patient's normal enrollment or safety during the study.
9. Prior immunotherapy for other tumors.
10. History of other malignant tumors within 5 years (excluding cured basal cell carcinoma of the skin or thyroid cancer).
11. Pregnant or lactating women.
12. Concurrently suffering from other malignant tumors.
13. Cannot or unwilling to sign the informed consent form.
14. Vaccination within 4 weeks.
15. Allergic reaction to the investigational drug.

Where it's running

• Ruijin Hospital, Shanghai Jiaotong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Yujie Wang, M.D.
• Email: wyj12054@rjh.com.cn
• Phone: +86 02164370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sintilimab Plus Hypofractionated Radiotherapy Then Chemoradiotherapy for Locally Advanced Head and Neck Cancer

  This study tests whether giving sintilimab with a short, high-dose radiotherapy course followed by standard chemoradiotherapy helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07781072

• Omitting Postoperative Cervical Radiation in Select Head and Neck Cancer Patients

  We’re testing whether leaving out some neck radiation after surgery is safe and could reduce side effects for adults with locally advanced head and neck squamous cell carcinoma who had neck dissections and no high-risk nodal factors.

  Recruiting Phase 2 Institut Català d'Oncologia · L'Hospitalet de Llobregat, Barcelona · NCT07755449

• Becotatug vedotin plus PD-1 inhibitor versus PD-1 inhibitor alone for EGFR‑positive resectable locally advanced head and neck cancer

  This trial will test if adding becotatug vedotin to a PD‑1 blocker given before and after surgery helps people with EGFR‑positive, CPS≥1 resectable locally advanced head and neck cancer do better than a PD‑1 blocker alone.

  Recruiting Phase 3 Sun Yat-sen University · Zhuhai, Guangdong · NCT07524452

• Low-dose radiotherapy plus anti–PD-1 immunotherapy before surgery for resectable locally advanced head and neck cancer

  This will test whether giving low-dose radiation together with two cycles of an anti–PD‑1 drug before surgery helps people with resectable locally advanced head and neck squamous cell carcinoma (CPS ≥1).

  Recruiting Phase 2 Fifth Affiliated Hospital, Sun Yat-Sen University · Guangdong · NCT07371234

• Comparing smaller, targeted surgery versus standard surgery after pre-surgery immunotherapy for locally advanced head and neck cancer

  This trial tests whether smaller, response-guided surgery instead of the usual larger operation after neoadjuvant PD-1‑based chemoimmunotherapy works for people with resectable locally advanced head and neck squamous cell carcinoma who had a partial or complete response.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07369882

• MRG003 alone or with the PD‑1 drug pucotenlimab before chemoradiotherapy for locally advanced head and neck squamous cell carcinoma

  This trial will test whether giving MRG003 alone or together with the PD‑1 drug pucotenlimab before standard chemoradiotherapy helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Groupe Oncologie Radiotherapie Tete et Cou · Villejuif · NCT06959108

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.